---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028081"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:10:55.425819+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged

## Summary
- JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.
- Heme Foundation pledges up to $10M over project; $2M already invested in prototypes and compounds.
- Total development cost estimated $20M-$25M over 3.5 to 5 years; Bioxytran retains IP.
- Two successful small animal trials (mice, rabbits) completed; large 14-day toxicology study planned.
- UOC compatible with all blood types, shelf-stable 5+ years, 18-hour half-life, no known side effects.

## SEC filing metadata
- accession: 0001493152-24-028081
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315224028081/0001493152-24-028081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315224028081/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028081
- JSON: https://secwatch.observer/filing/0001493152-24-028081.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.